Prevention of Metabolic Syndrome in Serious Mental Illness

Psychiatric Clinics of North America

Volumn 34, Issue 1, 2011, Pages 109-125

  Ganguli, Rohan ^a,b   Strassnig, Martin ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antipsychotic medication; Lifestyle management; Mental illness; Metabolic syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARIPIPRAZOLE; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAMOTIDINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA; ZIPRASIDONE;

BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; LIFESTYLE MODIFICATION; LIVER TOXICITY; MENTAL DISEASE; METABOLIC SYNDROME X; MONITORING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION EDUCATION; NUTRITIONAL COUNSELING; OBESITY; PRIORITY JOURNAL; PSYCHOEDUCATION; REINFORCEMENT; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; METABOLIC SYNDROME X; OBESITY; PREVENTIVE HEALTH SERVICES; PRIMARY PREVENTION;

EID: 79951564154     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2010.11.004     Document Type: Review

References (98)

1. Kraepelin E., Barclay R.M., Robertson G.M. Dementia praecox and paraphrenia 1919, E. & S. Livingstone, Edinburgh (UK).
2. Colton C.W., Manderscheid R.W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3(2):A42.
3. Hennekens C.H., Hennekens A.R., Hollar D., et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005, 150(6):1115-1121.
4. Tsuang M.T., Woolson R.F., Fleming J.A. Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry 1980, 37(9):979-983.
5. Mortensen P.B., Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993, 163:183-189.
6. Felker B., Yazel J.J., Short D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr Serv 1996, 47(12):1356-1363.
7. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997, 171:502-508.
8. Osby U., Correia N., Brandt L., et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000, 45(1-2):21-28.
9. Osby U., Brandt L., Correia N., et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001, 58(9):844-850.
10. Laursen T.M., Munk-Olsen T., Nordentoft M., et al. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 2007, 68(6):899-907.
11. McEvoy J.P., Meyer J.M., Goff D.C., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80(1):19-32.
12. Meyer J., Loh C., Leckband S.G., et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006, 12(1):5-10.
13. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359.
14. Fagiolini A., Frank E., Scott J.A., et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005, 7(5):424-430.
15. Taylor V., Macdonald K., McKinnon M.C., et al. Increased rates of obesity in first-presentation adults with mood disorders over the course of four-year follow-up. J Affect Disord 2008, 109(1-2):127-131.
16. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
17. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49(4):403-414.
18. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119(10):812-819.
19. Meigs J.B., Wilson P.W., Fox C.S., et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006, 91(8):2906-2912.
20. Kahn J.G., Kronick R., Kreger M., et al. The cost of health insurance administration in California: estimates for insurers, physicians, and hospitals. Health Aff (Millwood) 2005, 24(6):1629-1639.
21. Lawrence D., Mitrou F., Zubrick S.R. Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health 2009, 9:285.
22. Gregg E.W., Cheng Y.J., Cadwell B.L., et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005, 293(15):1868-1874.
23. Pi-Sunyer F.X. The medical risks of obesity. Postgrad Med 2009, 121(6):21-33.
24. Hubert H.B., Feinleib M., McNamara P.M., et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67(5):968-977.
25. Manson J.E., Colditz G.A., Stampfer M.J., et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990, 322(13):882-889.
26. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156(11):1686-1696. [see comment].
27. Dickerson F.B., Brown C.H., Daumit G.L., et al. Health status of individuals with serious mental illness. Schizophr Bull 2006, 32(3):584-589.
28. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223. [see comment].
29. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25(10):567-579.
30. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004, 65(2):267-272. [see comment].
31. Diabetes Prevention Program Research Group The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002, 25(12):2165-2171.
32. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344(18):1343-1350. [see comment].
33. Redmon J.B., Bertoni A.G., Connelly S., et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. Diabetes Care 2010, 33(6):1153-1158.
34. Klein S., Burke L.E., Bray G.A., et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004, 110(18):2952-2967.
35. Despres J.P. Is visceral obesity the cause of the metabolic syndrome?. Ann Med 2006, 38(1):52-63.
36. You T., Nicklas B.J. Chronic inflammation: role of adipose tissue and modulation by weight loss. Curr Diabetes Rev 2006, 2(1):29-37.
37. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16(6):397-415.
38. Pasanisi F., Contaldo F., de Simone G., et al. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 2001, 11(6):401-406.
39. Lee M., Aronne L.J. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007, 99(4A):68B-79B.
40. Kelley D.E., Wing R., Buonocore C., et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993, 77(5):1287-1293.
41. Wing R.R., Koeske R., Epstein L.H., et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987, 147:1749-1753.
42. Dattilo A.M., Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56(2):320-328.
43. Eckel R.H., Yost T.J. HDL subfractions and adipose tissue metabolism in the reduced-obese state. Am J Physiol 1989, 256(6 Pt 1):E740-E746.
44. Wadden T.A., Anderson D.A., Foster G.D. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: some findings and some questions. Obes Res 1999, 7(2):170-178.
45. Rossner S., Bjorvell H. Early and late effects of weight loss on lipoprotein metabolism in severe obesity. Atherosclerosis 1987, 64(2-3):125-130.
46. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II. Arch Intern Med 1997, 157:657-667.
47. Ganguli R., Cohn T., Faulkner G. Behavioural treatments for weight management in schizophrenia. Medical illness and schizophrenia 2009, 203-220. American Psychiatric Publishing, Inc, Arlington (VA). J. Meyer, H. Nasrallah (Eds.).
48. Harmatz M.G., Lapuc P. Behavior modification of overeating in a psychiatric population. J Consult Clin Psychol 1968, 32(5):583-587.
49. Rotatori A.F., Fox R., Wicks A. Weight loss with psychiatric residents in a behavioral self control program. Psychol Rep 1980, 46(2):483-486.
50. Littrell K.H., Hilligoss N.M., Kirshner C.D., et al. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003, 35(3):237-241.
51. Evans S., Newton R., Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 2005, 39(6):479-486.
52. Brar J.S., Ganguli R., Pandina G., et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005, 66(2):205-212. [see comment].
53. Weber M., Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006, 83(1):95-101.
54. Jean-Baptiste M., Tek C., Liskov E., et al. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res 2007, 96(1-3):198-205.
55. Khazaal Y., Fresard E., Rabia S., et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res 2007, 91(1-3):169-177.
56. Wu J.C., Gillin J.C., Buchsbaum M.S., et al. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry 1992, 149(4):538-543.
57. Cavazzoni P., Tanaka Y., Roychowdhury S.M., et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003, 13(2):81-85.
58. Poyurovsky M., Tal V., Maayan R., et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004, 14(4):332-336.
59. Baptista T., Hernandez L., Prieto L.A., et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001, 62(8):653-655.
60. Morrison J.A., Cottingham E.M., Barton B.A. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002, 159(4):655-657.
61. Baptista T., Martinez J., Lacruz A., et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006, 51(3):192-196.
62. Wu R.R., Zhao J.P., Jin H., et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008, 299(2):185-193.
63. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
64. Jones P.B., Barnes T.R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63(10):1079-1087.
65. Correll C.U., Manu P., Olshanskiy V., et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302(16):1765-1773.
66. Sikich L., Frazier J.A., McClellan J., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165(11):1420-1431.
67. Weiden P.J., Newcomer J.W., Loebel A.D., et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008, 33(5):985-994.
68. Newcomer J.W., Campos J.A., Marcus R.N., et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008, 69(7):1046-1056.
69. Kolotkin R.L., Corey-Lisle P.K., Crosby R.D., et al. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. Eur Psychiatry 2008, 23(8):561-566.
70. Fenton W.S., Chavez M.R. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 2006, 163(10):1697-1704. [quiz: 1858-9].
71. Fontaine K.R., Heo M., Harrigan E.P., et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001, 101(3):277-288.
72. Zhang Z.J., Yao Z.J., Liu W., et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004, 184:58-62.
73. Graham K.A., Perkins D.O., Edwards L.J., et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005, 162(1):118-123. [see comment].
74. Newcomer J.W. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006, 67(Suppl 9):25-30. [discussion: 36-42].
75. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132(6):2169-2180.
76. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365(9468):1415-1428.
77. Dervaux N., Wubuli M., Megnien J.L., et al. Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects. Atherosclerosis 2008, 201(2):413-417.
78. Fox C.S., Massaro J.M., Hoffmann U., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116(1):39-48.
79. Druss B.G., Marcus S.C., Campbell J., et al. Medical services for clients in community mental health centers: results from a national survey. Psychiatr Serv 2008, 59(8):917-920.
80. Southwood R.L. Have clinical studies demonstrated diabetes prevention or delay of diabetes through early treatment?. Am J Ther 2010, 17(2):201-209.
81. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51(9):2796-2803.
82. Azen S.P., Peters R.K., Berkowitz K., et al. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998, 19(2):217-231.
83. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368(9541):1096-1105.
84. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359(9323):2072-2077.
85. Torgerson D.J., Hauptman J., Boldrin M.N., et al. Xenixal in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004, 27:155-161.
86. Ratner R., Goldberg R., Haffner S., et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005, 28(4):888-894.
87. Baptista T., Rangel N., El Fakih Y., et al. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 2009, 42(1):14-19.
88. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457-2471.
89. Hanssens L., De Hert M., Kalnicka D., et al. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 2007, 22(1):43-49.
90. Schuster H., Fox J.C. Investigating cardiovascular risk reduction-the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004, 5(5):1187-1200.
91. Stalenhoef A.F., Ballantyne C.M., Sarti C., et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005, 26(24):2664-2672.
92. Vaughan C.J., Gotto A.M. Update on statins: 2003. Circulation 2004, 110(7):886-892.
93. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
94. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004, 64(22):2537-2565.
95. Druss B.G., Rohrbaugh R.M., Levinson C.M., et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry 2001, 58(9):861-868. [see comment].
96. Callahan R.C., Boire M.D., Lazo R.G., et al. Schizophrenia and incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. Schizophr Res 2009, 115:325-332.
97. Druss B.G., von Esenwein S.A., Compton M.T., et al. A randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry 2010, 167(2):151-159.
98. Kilbourne A.M., Post E.P., Nossek A., et al. Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. Psychiatr Serv 2008, 59(7):760-768.